Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma

Inclusion Criteria:

Untreated or relapsed/refractory follicular, SLL or MZL (i.e. no limit to number of prior treatments as long as patients meet other study criteria)
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
Measurable tumor size (at least one node measuring 4 cm^2 in bidimensional measurement)
Expected survival of > 6 months
Prior rituximab or other monoclonal immunotherapy permitted and eligible for rituximab monotherapy
Full recovery from any significant toxicity associated with prior surgery, radiation therapy, chemotherapy, or immunotherapy
Absolute neutrophil count > 1.0 x 10^9/L
Platelets > 50 x 10^9/L
Patients may receive erythropoietin growth factors to maintain adequate hemoglobin levels (>= 8.0 mg/dl)
Creatinine < 1.5 x upper normal levels (UNL)
Total bilirubin < 1.5 mg/dL (> 25.65 umol/L)
Aspartate aminotransferase < 5 x UNL
Alkaline phosphatase < 5 x UNL
Informed consent approved in institutional review board (lRB)
CD20+ B-cell lymphoma

Exclusion Criteria:

Prior history of human immunodeficiency virus (HIV)-positivity (routine HIV testing is required pretreatment)
Serious non-malignant disease (e.g. active uncontrolled bacterial, viral, or fungal infections) or other conditions which, in the opinion of the principal investigator would compromise other protocol objectives
Presence of central nervous system (CNS) lymphoma
Chemotherapy within 4 weeks of the first scheduled study treatment
Another primary malignancy (other than squamous or basal cell carcinoma of the skin or in-situ carcinoma of the cervix) for which the patient has not been disease-free for at least five years
Major surgery, other than diagnostic surgery, within four weeks
Patients with non-Hodgkin lymphoma (NHL) other than relapsed/refractory follicular, MZL or SLL
Patients must not have a history of cardiac disease, defined as New York Heart Association Class II or greater or clinical evidence of congestive heart failure
Concurrent use of other investigational agents
Pregnant or breast feeding
Subjects of reproductive potential who are not using adequate contraceptive precautions, in the judgment of the investigator
Known hypersensitivity to any recombinant E coli-derived product, murine proteins, or any components of the study medications
Concerns for the subject's compliance with the protocol
Any premalignant myeloid condition or any malignancy with myeloid characteristics (e.g. myelodysplastic syndromes, acute or chronic myelogenous leukemia)
Patient is currently enrolled in, or has not yet completed at least 30 days since ending another investigational device or drug trial